1. MD Anderson establishes new $50M+ biotech fund to choose next promising cancer therapies — Will the FDA panel meeting on COVID vaccines be the most watched FDA meeting ever? — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Celgene's partnership with Bluebird & Juno

Discussion in 'Celgene' started by anonymous, Dec 11, 2017 at 12:10 PM.

  1. anonymous

    anonymous Guest

    Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017.

    I think it's an advantage for all the three companies involved; especially for Bluebird Bio.
     

  2. anonymous

    anonymous Guest

    ASCO ‘18 not so impressive but very tough patient population. How will Wall Street react?
     
  3. anonymous

    anonymous Guest

    ASH 2017???
     
  4. anonymous

    anonymous Guest

    bluebird is a disorganized one trick pony with a extremely expensive treatment. Other biotech companies are catching up and everyone knows it